TCB-32

• Description:

  TCB-32 (Compound I-1) is a FGFR1 agonist with an EC50 of 0.88 μM. TCB-32 significantly increases cell proliferation through activating FGFR1 signaling pathway as bFGF and its downstream ERK 1/2 with excellent thermal stability. TCB-32 can replace bFGF in serum-free cell culture media. TCB-32 can be used for tissue repair and wound healing related diseases like psoriasis and eczema research[1][2].

• UNSPSC:

  12352005

• Target:

  ERK; FGFR

• Related Pathways:

  MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Others

• Smiles:

  C/C(C1=CC(NC(C2=CC(C(NC3=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C3)=O)=CC=C2)=O)=CC(/C(C)=N/NC(N)=N)=C1)=N\NC(N)=N

• Molecular Formula:

  C32H40N18O2

• Molecular Weight:

  708.78

• References & Citations:

  [1]FEOFANOV M, et al. Compounds for activation of fgfr1 signaling. WO2025045826A1. 2025-03-06. |[2]Feofanov M, et al. Discovery and optimization of a guanylhydrazone-based small molecule to replace bFGF for cell culture applications. Biochem Biophys Rep. 2025 Jul 21;43:102167.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  ERK1; ERK2; FGFR1

• CAS Number:

  [352513-86-1]